Faruqi & Faruqi Investigates Potential Claims
Faruqi & Faruqi, LLP is currently looking into the situation surrounding MoonLake Immunotherapeutics (NASDAQ: MLTX). Investors who incurred losses are encouraged to reach out directly to discuss their rights and possible courses of action. This firm is known for its strong record in securities litigation, providing much-needed support to investors during challenging times.
Understanding Your Legal Options
Any investor who acquired securities of MoonLake between the periods of March 10, 2024 and September 29, 2025 should consider the legal avenues available. By contacting Faruqi & Faruqi's partner, Josh Wilson, investors can obtain personalized legal guidance. The firm’s reputation is built on its commitment to fighting for the rights of investors and seeking justice on their behalf.
Background on the Investigation
Recent developments have raised concerns regarding MoonLake’s compliance with federal securities laws. Allegations suggest that the company, along with its executives, may have issued misleading statements about the efficacy and safety of their drug offerings. These potential infractions could significantly affect investor trust and company valuation.
Key Allegations Against MoonLake
The core of the allegations suggests that MoonLake failed to appropriately disclose crucial information concerning its product SLK in comparison to BIMZELX, which is another treatment for inflammatory conditions. Investors are particularly alarmed by claims that the company may not have a valid basis for asserting the superiority of SLK over other treatments.
The Impact of Recent Announcements
On September 28, 2025, MoonLake revealed the results of its Phase 3 VELA program. Unfortunately, these results demonstrated that SLK did not achieve expected efficacy compared to BIMZELX. The aftermath of this announcement was harsh; the company’s stock plummeted dramatically by nearly 90%, creating significant concerns among shareholders.
What It Means for Shareholders
For shareholders, the most pressing question now is the ability to recoup their investments. The court appoints a lead plaintiff from within the investor community to represent the interests of the entire group. This role is pivotal in moving the class action forward. Interested parties are encouraged to either volunteer for this role or stay engaged in the proceedings to protect their rights.
Gathering Evidence for Claims
Faruqi & Faruqi requests anyone with substantive information about MoonLake’s practices to come forward. This includes whistleblowers, former employees, and other stakeholders who can provide insights relevant to the ongoing investigation. Joining forces with legal experts can help drive accountability.
Steps to Take for Investors
If you're an investor in MoonLake Immunotherapeutics and feel you’ve been adversely affected, you have several options. The first step may be to contact an attorney with experience in securities law, such as those at Faruqi & Faruqi. They can help you understand your rights, evaluate your position, and offer guidance on the next steps to take.
Resources Available to Investors
To get further information on this situation, interested investors can visit the Faruqi law firm’s website or call their office for personalized assistance. Keeping informed about your investment and understanding your rights is crucial during this time. Faruqi & Faruqi is committed to advocating for their clients by harnessing their extensive legal knowledge and experience.
Frequently Asked Questions
What is Faruqi & Faruqi doing about the investigation?
Faruqi & Faruqi is investigating potential claims related to misleading statements made by MoonLake Immunotherapeutics.
How can I contact Faruqi & Faruqi?
Investors can reach out to Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for direct communication.
What happens if I'm a member of the class action?
If chosen, a lead plaintiff will represent the interests of the class in court, and you may or may not need to actively participate.
When did the issues with MoonLake arise?
The issues became significantly apparent after the disappointing Phase 3 VELA program results announced on September 28, 2025.
What can investors do now?
Investors should consult legal counsel and stay informed about the investigation’s progress to protect their interests.
